View Older Stories View More Recent Stories

Jan 2, 2024 06:00AM Exact Sciences to participate in J.P. Morgan Healthcare Conference
Dec 7, 2023 08:05AM Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings
Nov 30, 2023 04:05PM Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients
Nov 17, 2023 07:11AM Exact Sciences (EXAS) Files Patent Infringement Lawsuit Against Geneoscopy
Nov 17, 2023 07:10AM Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
Nov 1, 2023 04:05PM Exact Sciences Announces Third-Quarter 2023 Results
Nov 1, 2023 06:00AM Exact Sciences to participate in November investor conferences
Oct 22, 2023 03:00PM Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detectio
Oct 20, 2023 06:08PM Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress
Oct 9, 2023 06:00AM Exact Sciences schedules third quarter 2023 earnings call
Oct 9, 2023 05:58AM Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
Sep 12, 2023 08:35AM Agilent Technologies (A) and Exact Sciences (EXAS) Agree to Terms of Sale for Resolution Bioscience
Sep 12, 2023 08:35AM Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
Sep 1, 2023 06:00AM Exact Sciences to participate in September investor conference
Aug 30, 2023 07:30AM Exact Sciences (EXAS) and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials
Aug 30, 2023 07:30AM Exact Sciences Lab and OncoExTra Test Selected by National Cancer Institute for ComboMATCH Clinical Trials
Aug 21, 2023 07:57AM Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings
Aug 1, 2023 04:05PM Exact Sciences Announces Second-Quarter 2023 Results
Jul 10, 2023 06:00AM Exact Sciences schedules second quarter 2023 earnings call
Jun 21, 2023 07:18AM Exact Sciences (EXAS) announces separate collaborations with two renowned healthcare organizations
Jun 21, 2023 07:14AM Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
Jun 20, 2023 04:05PM Exact Sciences (EXAS) Reports New Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity
Jun 20, 2023 04:05PM Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening
Jun 1, 2023 08:00AM EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK® CERTIFICATION™
Jun 1, 2023 06:00AM Exact Sciences to participate in June investor conferences
May 26, 2023 06:58AM Exact Sciences (EXAS) Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing
May 26, 2023 06:58AM Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023
May 17, 2023 07:00AM EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS
May 9, 2023 04:05PM Exact Sciences Announces First Quarter 2023 Results
May 9, 2023 06:38AM Exact Sciences (EXAS) Presents New Data on CRC
May 9, 2023 06:37AM Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week® Annual Meeting
May 1, 2023 06:00AM Exact Sciences to participate in May investor conference
Apr 12, 2023 03:07PM Exact Sciences Presents Advancements in Cancer Detection at American Association for Cancer Research® 2023 Annual Meeting
Apr 10, 2023 06:00AM Exact Sciences schedules first quarter 2023 earnings call
Feb 23, 2023 09:29AM Exact Sciences (EXAS) Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Feb 23, 2023 09:29AM Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Feb 22, 2023 06:00AM Exact Sciences to participate in March investor conferences
Feb 21, 2023 04:05PM Exact Sciences Announces Fourth Quarter 2022 Results
Feb 7, 2023 08:29AM Exact Sciences (EXAS) Launches OncoExTra Cancer Therapy Selection Test in the U.S.
Feb 7, 2023 08:29AM Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
Feb 1, 2023 06:00AM Exact Sciences schedules fourth quarter 2022 earnings call
Jan 9, 2023 05:01AM Exact Sciences (EXAS) Guides Q4 Revenue of $551-$553M
Jan 8, 2023 03:45PM Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
Jan 3, 2023 06:00AM Exact Sciences to participate in J.P. Morgan Healthcare Conference
Dec 20, 2022 10:13AM Medicare and Insurance Policy Updates in 2023 Will Improve Cancer Screening Access by Removing Patient Colonoscopy Cost Following a Positive Cologuard Test
Dec 9, 2022 10:05AM Exact Sciences Presents First Time Data Detailing Ability to Predict Radiation Therapy Benefit in Breast Cancer Patients
Dec 6, 2022 04:05PM Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022
Nov 3, 2022 04:05PM Exact Sciences Announces Third Quarter 2022 Results
Nov 1, 2022 06:00AM Exact Sciences to participate in November investor conferences
Oct 24, 2022 07:35AM Exact Sciences (EXAS) Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology
View More Recent Stories View Older Stories